Postprandial Hypoglycemia
13
1
1
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.7%
1 terminated out of 13 trials
88.9%
+2.3% vs benchmark
15%
2 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
Canakinumab for the Treatment of Postprandial Hypoglycemia
Empagliflozin for the Treatment of Postprandial Hypoglycemia
The Scottish Fruit Study
Glucose Response to a Formula for Patients at Risk of Hypoglycaemia
Treatment of Post-bariatric Hypoglycaemia
Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy
Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.
Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)
Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia